Critical Path Institute's ® (C-Path) Translational Therapeutics Accelerator (TRxA) proudly announced today a $250,000 grant award aimed at developing a novel treatment for type 1 diabetes (T1D). Kyle ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback